Local low-dose urokinase treatment of acquired intracardiac thrombi in preterm infants.
We report three cases of intracardiac thrombi in preterm infants of very low birth weight, in whom local low-dose urokinase treatment achieved complete thrombolysis without any signs of systemic fibrinolytic activity or side-effects. This new treatment strategy seems to be safe, requires minimal monitoring of fibrinolytic activity, and may be a new option for thrombolysis in high-risk patients such as premature infants, patients recently operated on, and patients presenting with other contra-indications for systemic fibrinolytic therapy.
Aspesberro
F
F
Critical Care, Cardiology and Hematology-Oncology, Department of Pediatrics, Hôspital des Enfants, University Hospital of Geneva, Switzerland.
Beghetti
M
M
Oberhänsli
I
I
Ozsahin
H
H
Humbert
J
J
Rimensberger
P C
PC
D005260:Female; D006325:Heart Atria / Q000000981:diagnostic imaging; D006331:Heart Diseases / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D019102:Infant, Very Low Birth Weight; D008297:Male; D010960:Plasminogen Activators / Q000008:administration & dosage* / Q000627:therapeutic use; D012307:Risk Factors; D015912:Thrombolytic Therapy / Q000379:methods; D013927:Thrombosis / Q000188:drug therapy*; D016896:Treatment Outcome; D014463:Ultrasonography; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage* / Q000627:therapeutic use
D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator